News | EP Lab | May 28, 2020

Frequent Coffee Consumption Lowers Chance of Arrhythmias

New study aims to address the myths and anxiety around caffeine consumption among heart rhythm patients

HRS study finds Frequent Coffee Consumption Lowers Chance of Arrhythmias. #HRS #HRS20 Heartrhythm20

May 28, 2020 – A recent study revealed that drinking a couple of cups of coffee per day does not lead to a greater risk of arrhythmias. This potentially debunks a common myth that consuming caffeine in coffee and other drinks could lead to a faster heartbeat and the potential for a triggered arrhythmia for this patient population. Researchers analyzed several types of arrhythmias to better understand the impact of caffeine on this common heart condition. 

Results from this observational study were released as part of Heart Rhythm Society (HRS) 2020 Science virtual meeting in May.

Americans are dependent on their daily dose of caffeine, with more than 64 percent of Americans drinking a cup of coffee every day.[1] Patients with arrhythmias are often cautioned against regular consumption by their doctors. Despite this specific concern, caffeine also offers health benefits, including antioxidants, improved metabolism, enhanced exercise performance, and increased alertness and concentration.[2] Studies have also shown regular coffee consumption can also yield positive heart health results, lowering the risk of heart disease and stroke.[3] With evidence showing caffeine’s positive impact on general heart health, there is a need to better understand the relationship between regular coffee consumption and arrhythmias.

The study reviewed coffee intake information and relevant data for 296,227 participants in the U.K. Biobank. The biobank follows the health and well-being of 500,000 volunteer participants and provides health information to researchers.

The mean age of participants was 56.69 ± 7.98 and 51.6 percent of participants were female. Investigators used multivariate Cox proportional hazards regression analysis to test the association between coffee consumption and arrhythmia risk and plotted a Kaplan-Meier curve for cumulative incidence of arrhythmia by coffee intake.

The results demonstrated an association between regular coffee consumption and a significantly lower risk of arrhythmias. Over 5.25 ± 21 years, there were 13,138 incident arrhythmias diagnosed, including 4,748 patients with atrial fibrillation or atrial flutter, 798 supraventricular tachycardia, 386 ventricular tachycardia and 308 premature ventricular complex. Compared with no consumption, coffee consumption of 1-2, 3-4, or 5 or greater cups a day was associated with a significantly lower risk of arrhythmia (HR 0.90, p<0.0001; HR 0.86, p<0.0001; HR 0.85 p=0.0005; HR 0.88, P=0.05, respectively). Each additional daily cup of coffee was associated with three percent lower incidence of arrhythmia. 

Find more new and late-breaking studies from HRS 2020

 

Related Coffee Cardiology Content:

Coffee Associated With Reduced Risk of Heart Failure, Stroke

Coffee Consumption Associated With Lower Death Rate

Regular Caffeine Consumption Does Not Result in Extra Heartbeats

Cardiac MRI Reveals Energy Drinks Alter Heart Function

Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
 

 

References:
1. National Coffee Association. (2018). The 2018 National Coffee Data Trends Report. Retrieved from https://www.ncausa.org/Industry-Resources/Market-Research/NCDT.

2. Current Neuropharmacology Jan 2015, 13(1): 71-88; doi: 10.2174/1570159X13666141210215655.

3. Lopez-Garcia E, Rodriguez-Artalejo F, Rexrode KM, Logroscino G, Hu FB, van Dam RM. Coffee consumption and risk of stroke in women. Circulation. 2009;119:1116-23.
 


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now